Results 151 to 160 of about 11,060 (223)

Cost-effectiveness of implantable cardioverter-defibrillators for primary prevention in heart failure with reduced ejection fraction: a Markov model using JROAD-DPC cost data in Japan. [PDF]

Front Cardiovasc Med
Ohashi K, Watanabe M, Morii Y, Yokoshiki H, Kusano K, Imai K, Takagi M, Yamane T, Tada H, Ogasawara K.   +9 more
europepmc   +1 more source

Implantable cardioverter defibrillators for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia? (Not so fast, Louis). [PDF]

Europace
Schwartz PJ, Ackerman MJ.
europepmc   +1 more source

Phoenix from the Ashes: An Advocacy for an International Consensus for Return To Play for Athletes with Implantable Cardioverter Defibrillators. [PDF]

Sports Med Open
Müssigbrodt A.
europepmc   +1 more source

Safety and efficacy of radiofrequency ablation of benign thyroid nodules in patients with a history of implantable cardioverter defibrillators (ICDs), permanent pacemakers (PPMs), and implantable cardiac monitors (ICMs). [PDF]

Gland Surg
Bashumeel Y, Tsakiris E, Donthi S, AlSelek A, Noureldine SI, Kandil E.   +5 more
europepmc   +1 more source

Dynamic evaluation of atrial fibrillation risk factors using multiple sensors of implantable cardioverter defibrillators [PDF]

Europace
La Greca C, Dell'Aquila A, Prezioso A, Bertini M, Bianchi V, Vitulano G, Calò L, Savarese G, Santobuono VE, Dello Russo A, Viscusi M, Santoro A, Calvanese R, Pangallo A, Amellone C, Arena G, Campari M, Valsecchi S, Boriani G, Pecora D.   +19 more
europepmc   +2 more sources

Implantable cardioverter-defibrillators in ischaemic versus non-ischaemic heart failure: Insights from the VICTORIA trial. [PDF]

Eur J Heart Fail
Gouda P, Alemayehu W, Voors AA, Lam CSP, Ezekowitz J, Pieske B, Butler J, Westerhout CM, Yogasundaram H, Sandhu RK, Armstrong PW, on behalf of the VICTORIA Study Group.   +11 more
europepmc   +1 more source